Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca 2؉ from the intracellular Ca 2؉ store, the sarcoplasmic reticulum. In about 50% of cases, malignant hyperthermia susceptibility is linked to the gene encoding the skeletal muscle ryanodine receptor/Ca 2؉ release channel (RYR1). To date, eight point mutations have been identified in human RYR1. Although these mutations are thought to lead to an increased caffeine and halothane sensitivity in the contractile response of skeletal muscle, their functional consequences have not been investigated on the molecular level. In the present study, we provide the first functional characterization of a point mutation located in the central part of RYR1, Gly 2434 3 Arg. Using high affinity [
Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca 2؉ from the intracellular Ca 2؉ store, the sarcoplasmic reticulum. In about 50% of cases, malignant hyperthermia susceptibility is linked to the gene encoding the skeletal muscle ryanodine receptor/Ca 2؉ release channel (RYR1). To date, eight point mutations have been identified in human RYR1. Although these mutations are thought to lead to an increased caffeine and halothane sensitivity in the contractile response of skeletal muscle, their functional consequences have not been investigated on the molecular level. In the present study, we provide the first functional characterization of a point mutation located in the central part of RYR1, Gly 2434 3 Arg. Using high affinity [ 3 H]ryanodine binding as the experimental approach, we show that this mutation enhances the sensitivity of RYR1 to activating concentrations of Ca 2؉ and to the exogenous and diagnostically used ligands caffeine and 4-chloro-m-cresol. In parallel, the sensitivity to inhibiting concentrations of Ca 2؉ and calmodulin was reduced, transferring the mutant Ca 2؉ release channel into a hyperexcitable state.
Malignant hyperthermia (MH)
1 is a pharmacogenetic skeletal myopathy of humans and swine and is one of the main causes of death due to anesthesia. Predisposed patients are at high risk for undergoing a fulminant MH crisis when exposed to certain volatile anesthetics and depolarizing muscle relaxants commonly used in anesthesia. A point mutation (Arg 615 3 Cys) in the skeletal muscle ryanodine receptor (RYR1), which functions as the sarcoplasmic reticulum (SR) Ca 2ϩ release channel, has been linked to porcine stress syndrome, an equivalent to human MH (1) . Contrary to porcine stress syndrome, human MH is a genetically heterogeneous skeletal muscle disorder. Based on genetic linkage studies, three MH loci are known. The first has been mapped to chromosome 19q12-13.2 encompassing the gene that in homology with the animal model encodes the RYR1 (2, 3) , the second has been mapped to chromosome 7q including the gene for the ␣ 2 /␦ subunit of the skeletal muscle dihydropyridine receptor (4) , and the third has been mapped to chromosome 3q13.1 (5) . To date, mutations have only been identified in RYR1 that count for approximately 50% of human MH cases (reviewed in Ref. 6 ). MH mutations seem to cluster in two areas of the RYR1 sequence. Six mutations have been localized in the N-terminal sequence of RYR1 containing a homologous mutation to that identified in porcine MH-susceptible (MHS) muscle. Two further mutations have been found in the central amino acid sequence. In vitro, all these mutations induce a hypersensitivity of biopsied muscle to the contracture-triggering agents caffeine and halothane. This enhanced sensitivity is exploited in the diagnostic in vitro contracture test (IVCT). According to the European test protocol (7), dissected muscle fiber bundles are exposed to increasing concentrations of caffeine and halothane. Individuals are classified MHS if the sensitivity is increased for both compounds. Ca 2ϩ release from human SR vesicles obtained from MHN and MHS muscle samples has been studied in a few approches (8 -13) . In these experiments, however, MHS muscle samples were collected from genetically nonclassified material. Thus, the observed effects could not be addressed to a single human RYR1 mutation. In the present study, we characterized the functional effects of a human RYR1 mutation that is located in the central part of RYR1, Gly 2434 3 Arg. (The numbering of amino acids follows the corrected sequence data for the human RYR1 according to Ref. 14.) Our data provide the first definitive evidence that a centrally located mutation is causative for the hypersensitivity of SR Ca 2ϩ release in MHS muscle. Part of this work has been submitted in abstract form (15) .
EXPERIMENTAL PROCEDURES
Materials-Taq polymerase was purchased from Pharmacia (Freiburg, Germany), and AlwNI was from New England Biolabs (Schwalbach, Germany). A DNA preparation kit was obtained from MWG-Biotech (Ebersberg, Germany). (9, H(N))Ryanodine was purchased from DuPont NEN (Bad Homburg, Germany). Ryanodine was from Calbiochem (Bad Soden, Germany), and protease inhibitors were from Boehringer (Mannheim, Germany). Protein molecular mass standard was purchased from Bio-Rad (Mü nchen, Germany), and DNA size standard was from MBI Fermentas (St. Leon-Rot, Germany). All other chemicals were of analytical grade. Filter membranes for [ 3 H]ryanodine binding were purchased from Schleicher & Schü ll (Dassel, Germany).
Patient Characterization-Skeletal muscle biopsies (Musculus vastus lateralis) were taken from a patient who had suffered from a typical MH crisis and from his relatives for the test of susceptibility to MH. DNA was extracted from anticoagulated blood of individuals from this pedigree found to be heterozygous for the RYR1 Gly 2434 3 Arg mutation. For control, muscle specimens were obtained from individuals who had undergone muscle biopsy for exclusion of MH susceptibility. Muscle samples were tested according to the protocol of the European Malignant Hyperthermia Group (7) . All procedures were in accordance with the Helsinki convention and were approved by the Ethics Commission of the University of Ulm.
Amplification and Digestion of Genomic DNA-Genomic DNA was * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.isolated from 10 ml of blood from MHN and MHS individuals using a DNA preparation kit (MWG-Biotech). For analysis of mutation G7300A predicting the Gly 2434 to Arg substitution, flanking primers as designed from the published sequence (14) (Ex45RyR sense 5Ј-TTCCCTG-CAGCTTTGGTG-3Ј and Ex45RyR reverse 5Ј-GGGTCTCACATG-CATCTC-3Ј) were used to amplify a 128-bp fragment. PCR was carried out with 50 ng of genomic DNA and 30 pmol primers each in a total volume of 50 l. The PCR reaction contained 50 mM KCl, 20 mM Tris-HCl, pH 8.4, 2.5 mM MgCl 2 , 0.01% gelatin, 200 M of each dNTP, and 1 unit of Taq polymerase. PCR amplification conditions were 94°C for 4 min followed by 35 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 30 s. The presence or absence of the mutation was detected by polyacrylamide gel electrophoresis of products obtained by digestion of PCR products with AlwNI.
Preparation of SR Membranes-MHS muscle samples obtained by biopsy from the M. vastus lateralis were collected from five individuals carrying the RYR1 mutation Gly 2434 3 Arg. The patients consisted of five males, varying in age from 34 to 69 years. For control, muscle samples were obtained from 28 individuals who were classified MHN according to the European IVCT protocol (7). Biopsied muscle specimens were immediately frozen and stored in liquid nitrogen until use. A microsomal SR fraction was isolated as described previously (16) . Isolated membranes were resuspended in 0.3 M sucrose, 10 mM K-PIPES, pH 6.8, rapidly frozen in liquid nitrogen and stored at Ϫ70°C. To prevent proteolysis, the following protease inhibitors were included in various purification steps: 200 M Pefabloc (4-(2-aminoethyl)benzolsulfonyl-fluoride), 100 nM aprotinin, 1 M leupeptin, 1 M pepstatin A, and 1 mM benzamidine. Protein concentration was determined according to the method described in Ref. 17 using bovine serum albumin as a standard.
[
Binding-SR vesicles (at a protein concentration of 400 g/ml) were incubated with indicated concentrations of [ 3 H]ryanodine in a medium containing 100 mM KCl, 100 M EGTA, 20 mM Na-PIPES, 200 M Pefabloc, pH 6.8, for 3 h at 37°C. Varying concentrations of Ca 2ϩ , calmodulin, caffeine, and 4-chloro-m-cresol were added to the incubation medium as indicated in the figure legends. Unbound ryanodine was separated from protein-bound ryanodine by filtration of protein aliquots (14 g) through Schleicher & Schü ll GF51 filters presoaked in 1% polyethylenimine. Filters were washed three times with ice-cold buffer solution as described above. Radioactivity remaining with the filters was measured by liquid scintillation counting. Specific binding was calculated as the difference of total and nonspecific binding determined in the presence of a 1000-fold excess of unlabeled ryanodine. Experiments were carried out in duplicate.
Polyacrylamide Gel Electrophoresis-Protein samples were denatured in Laemmli buffer at 95°C for 3 min and separated in 3.5-15% gradient SDS/polyacrylamide minigels. Gels were stained with Coomassie Brilliant Blue. DNA fragments were separated in linear 10% polyacrylamide gels. Gels were stained with ethidium bromide.
Miscellaneous Methods-Free concentrations of Ca 2ϩ were calculated using the computer program and binding constants described in Ref. 18 . Dose-response curves were fitted using nonlinear curve-fitting routines based on the Marquardt-Levenberg algorithm. The data represent the means Ϯ S.D. of two different MHN and MHS SR preparations.
RESULTS
Human skeletal muscle specimens were obtained from patients who underwent muscle biopsy for the test of susceptibility to MH. For this purpose, the caffeine and halothane sensitivity of dissected fiber bundles of biopsied muscle were tested according to the European IVCT protocol. MHS samples were collected from individuals of one pedigree heterozygous for the RYR1 Gly 2434 3 Arg mutation. To investigate the presence of the mutation in this pedigree, the 128-bp region spanning the G7300A mutation was amplified and subjected to restriction enzyme analysis. The base exchange results in the creation of an AlwNI restriction site (19) . Digestion of PCR-amplified DNA fragments resulted in MHS individuals in two additional bands of 100 and 28 bp (Fig. 1) . Fig. 1 shows that the mutation segregated with MH. All patients who were classified MHS in IVCT carried the point mutation in RYR1. To investigate the functional consequences of this mutation at the molecular level, a microsomal SR fraction was isolated from MHS muscle and as control from MHN samples and utilized for high affinity vated binding in a concentration-dependent manner (Fig. 5) . Contrary to the porcine Arg 615 3 Cys mutation (30), the human Gly 2434 3 Arg mutation resulted in a loss of sensitivity for CaM. In MHN vesicles, CaM inhibited binding to about 30% of control, whereas binding to MHS vesicles was only reduced to 50%. Significant differences were found in the presence of CaM concentrations greater than 0.1 M.
In the following experiments, the effects of the two exogenous RYR1 activators, caffeine and 4-chloro-m-cresol, which are used for the diagnosis of MH, were investigated. Experiments were carried out in the presence of a free Ca 2ϩ concentration of 0.1 M, which is below the threshold of activation for both vesicle types. Similar to Ca 2ϩ , caffeine stimulated [ 3 H]ryanodine binding to a higher level to MHS than to MHN vesicles (Fig. 6, left) . Major differences between MHN and MHS vesicles were observed for concentrations starting at 5 mM. The stimulatory effect, however, was weak compared with caffeine-activated [ (Table I ). The calculated EC 50 values were about 24.9 mM for MHN and 9.5 mM for MHS vesicles.
It has recently been shown that 4-chloro-m-cresol (4-CmC) is a potent and specific activator of RYR1 that can be used as a diagnostic tool to distinguish between MHN and MHS muscle (16, (31) (32) (33) (Fig. 6, right) . Contrary to caffeine, the absolute level of activation was about 2-fold higher, and the resulting EC 50 values were approximately 20-fold lower. MHS vesicles were about 3-fold more sensitive (EC 50 ϭ 190 M (n ϭ 3)) compared with MHN (EC 50 ϭ 535 M (n ϭ 8)). The largest differences in activation were observed at 4-CmC concentrations between 200 and 500 M.
DISCUSSION
The sarcoplasmic reticulum (SR) is the major element in skeletal muscle that regulates the release and uptake of myoplasmic Ca 2ϩ . SR Ca 2ϩ release is mediated by the high molecular weight ligand-gated Ca 2ϩ release channel (RYR1), which is biochemically characterized by its high affinity for the plant alkaloid ryanodine (recent reviews in Refs. 34 and 35) . The protein complex comprises four identical subunits each consisting of about 5000 amino acids as deduced by cloning and sequencing of the cDNA (36, 37) . Hydropathy plots suggested 4 (rabbit RYR1) to 10 (human RYR1) hydrophobic segments, the ion pore forming segments in the C-terminal part, comprising about 10 -20% of the receptor molecule. The remainder of the protein has been assigned to the cytoplasmic side of the SR membrane. Human RYR1 mutations have been linked to two skeletal muscle diseases, malignant hyperthermia and central core disease (CCD) (6, 38 -40) . Both disorders have been associated with an abnormally high release of Ca 2ϩ from SR, which is probably due to an altered function of the mutant Ca An A for G7300 transition in the RYR1 gene leads to the replacement of a conserved Gly by an Arg at position 2434 in the amino acid sequence. This mutation has been identified in four Caucasian (19) and four Canadian pedigrees (41) . Comparing the presence or the absence of the mutation in the pedigree investigated in the present study with the results of the in vitro contracture test (Fig. 1) (20 -22) . Using this highly reproducible functional approach, we were able to investigate the effects of some major endogenous and pharmacological ligands of RYR1. (42) . In contrast to the material obtained from humans who were heterozygous for the Gly 2434 3 Arg mutation, porcine muscle was obtained from pigs that were homozygous for the Arg 615 3 Cys mutation. [ Porcine MHS SR vesicles exerted an approximately 4-fold higher affinity for [ 3 H]ryanodine compared with MHN vesicles. This difference is less pronounced for the human mutation. The smaller difference could be either explained by the different locations of the mutations in the amino acid sequence, or it could be due to the fact that the human muscle is heterozygous for the mutation. A heterozygous RYR1 mutation should result in five different populations of RYR1 tetramers: homotetramers consisting of only normal or mutant subunits, respectively, and heterotetramers consisting of one to three mutant sub- concentrations. We also observed a distinct lower sensitivity of human SR vesicles for caffeine, whereas 4-CmC activated binding to porcine and human SR in a similar concentration range. In all cases, however, both the human and the porcine mutation induced a similar shift in the EC 50 values to lower and, for inhibiting Ca 2ϩ , to higher concentrations. Differences in the functional consequences of both mutations were observed for the inhibitory effect of CaM in that the mutant human RYR1 was less sensitive to inhibiting CaM concentrations compared with the MHN receptor (Fig. 5) . A similar tendency has also been described for the mutant porcine receptor (30) . These differences in inhibition, however, were not found to be significant. The distinct lower sensitivity of the human MHS receptor can be explained by the close vicinity of CaM binding sites to the Gly 2434 3 Arg mutation (30, 44, 45) . The mutant porcine receptor has been found more sensitive to activating CaM concentrations in the absence of Ca 2ϩ (30) . We also investigated this effect on the human mutation. CaM activation of [ 3 H]ryanodine binding to human SR vesicles in the absence on Ca 2ϩ , however, was so low that it was not possible to visualize differences in activation between MHN and MHS vesicles.
In conclusion, our data show that the porcine Arg 615 3 Cys and the human Gly 2434 3 Arg mutation induce similar shifts in sensitivities of RYR1 toward some major endogenous ligands and to compounds that are utilized in the diagnosis of MH. It might be tempting to speculate that in the three-dimensional conformation the N-terminal and central part of RYR1 are in close vicinity. The mutations in this area may be acting in a similar manner in transferring the Ca 2ϩ release channel into a hypersensitive state.
